for Conference afternoon. Third Good Jee. XXXX Penumbra's joining Thank Quarter you, Thank you Call.
quarter year-over-year as for Our basis. a third on reported total constant the $XXX.X of revenues increase currency million, and XX.X% were XX.X% a
of basis. worldwide XX% record growing revenue business achieved a year-over-year million, on $XXX.X Our thrombectomy
worldwide revenue increasing a same year was Our other and over embolization the million, X.X% $XX.X ago. period
Our XX.X% global vascular We led year-over-year. increasing led strong thrombectomy, neurothrombectomy had quarter million XX.X% year-over-year, XX.X% growth U.S. thrombectomy in $XXX.X another year-over-year. very business States United year-over-year, XX.X% by our the revenue total increased to grew of grew which as while
quarter, how and thrombectomy launches for X not Our the is which growth had stroke in of year in products. new did demand this during have we product our computer-assisted building first thrombectomy strong as shows we've quarters the vacuum
accelerate quarter and in embolization access to fact, third In the United growth, both slightly similar total our on to expect we States basis in and year-over-year we to quarter. in and globally the a fourth the thrombectomy expect growth be
was quarter of a million XX% income total or revenue year. posted to operating last $XX.X of of third revenue. million representing $XX.X record quarter adjusted gross the with history. third We expanded investments and expansion quarter third made company's execution disciplined our the in margins commercial operating quarter most Non-GAAP margin Strong our XX.X%. revenue the million quarter last We X.X% EBITDA and growth record coupled compared $XX.X in the XX.X% to profitable in and gross
sequentially. by also our cash operating $XX.X We million grew balance
XX the been this years head led the innovative margin mission. in and transformational strong company's company toe Almost beyond. to wherever the largest our strong always thrombus the expect Penumbra our to gross moment successes body, we history forward, out and from is proprietary in of XXXX, incremental it of is in to profit growth, expansion, revenue XXXX Looking world thrombectomy margins and flow take developing technologies deliver cash has and thrombectomy have to increasing market.
We RED elements momentum. speed X clot currently important the X ascended vacuum thrombectomy most and driving successfully that Lightning optimize XX computer-assisted safety, developed Bolt removal, are and proprietary and simplicity. our of products have now Lightning Flash
Because extraordinary milestone expect an during these to we the products, achieve quarter. of fourth
to notable our expect United each in treat products. with have to help significant X,XXX,XXX than team. But alone We is and a obviously our during States burden. our XXX,XXX XXXX in more go physician thrombectomy to that clot customers patients U.S. the achievement the clot year for have this way a We still the patients long
our This delivered or we In total X arterial we thrombectomy, was strong and accounts, using franchises. growth customer and bolt. with a for U.S. venous hospitals flash had X,XXX which achieved quarter. define strong success third Lightning either Bolt vascular as Lightning Flash over
in So twice both counted they products. using are if are cases, some hospitals
these typical As the over in working mentioned, an or now process number prior orders. new pending of accounts, on succeeded just placing obtaining to initial to well XXX which addition through accounts approvals I supply in are And the update are their we last flash quarter those Bolt. chain for VAC
We expect this order begin many or using bolt flash to of these and quarter. customers
XXXX. in to first bolt use be Therefore, as currently on of potential least of customer working or expect open or to flash base in and CAVT VAC or the cases available initial to Once accounts lytic during expect currently mechanism. with addition, half surgery accounts process will we our the at use of additional deeper starting the have we QX XXX we of increasing order their going and are most have through In still majority QX products primary training and of that work those these the the that our used shelves are XXXX. shifts
to and already still over catheters curve both stroke product we've that XX% that share the flash process sended of as share rest XX have the this compared many launched of through against we We hospitals for market reorder with work aspiration thrombectomy. competing in far, for from In stroke the well. other currently So the are any its ever in rates other we gaining as as Bolt majority U.S. market. are in submission aspiration as catheters XX for each are technology RED the early product the estimate thrombectomy, is adoption position. high our
Looking for innovation the our the SENDit drive can forward, The share X the XX% asked procedure, trackability believe most our procedure, are. stroke RED the by to new we end over coupled namely investors several with with technology front end XX questions next of of get Thunderbolt both back with for extraction we years. the clot the our plus
aren't the is ready to patients we in opportunity doing thrombectomy to are thrombectomy? specific second, of meet than today. the ahead is, the moment I receiving question and before. CAVT yes, confident am to to First, our think what bigger team moment XX% answer of work first able to who Penumbra understands and bring ever this And the other The is meet that serious work
areas Now the work without sharing ahead. me competitive specific of outline information, let
and growth. on innovation, internal readiness work of after long-term X focused companies is access work areas: modeled Our [indiscernible] implementation the for market sustainable work
robust. innovation our pipeline First, is
We are well for as is systems vacuum physician hearing thrombectomy. as thrombectomy computer-assisted hospital that the our customers from future standard
the Bolt share and United with PE CAVT both DVT, in plan will Over our the we and to X and market X, products new CAVT launch drive portfolio months, expect arterial. flash States. growth Coupled we market next in XX
over the term. technology dominance the that of these long platform scope new have could In next-generation we in and term, with products addition expand CAVT our the made coming advancements both to near significant
and to We future. to be say will now, physician these that be for unique platform talk further But I customers these our developments use. provide will about our into their more able including in CAVT the benefits physician technologies hospitals, outcomes and will patient will integrated optimizing and
area readiness. second internal is The
We acquisition, have supply which utilization. work manufacturing started raw chain includes efficient stable efficient already and at capacity serious on scale, material
efficiency team marries scale on field appropriate in has to X well support [indiscernible]. our market-leading vascular. course, to with are our movement started continuing bring thrombectomy enabling even grow evolving to launching coronary an focus our to of We the a thrombectomy our team, customer order teams, sales and stronger portfolio lot processing to commercial we current profitability. with in have Currently, and investment And transformative product that embolization focused time more with also work our plus our faster we believe new products particularly and and on,
X of the We stronger in putting will position team opportunity advantage over in evolve an a the even to in take quarters, team next the XXXX thrombectomy. commercial and beyond
is Kaptamala, Together strong Internally, implement are being the interventional and advantages our access Beninati, and work substantiate and of Chief Medical over long CAVT based senior with Penumbra the the including surgery, reimbursement best-in-class programs Officer Dr. a historical starting with initiative Jim focused refer term. Ben interventional we We on market our our it cardiology closely in platform. to Officer; in this concert Dr. specialties Associate believe by we neuro the leaders commercial platform with and external and leaders will intervention. Medical CAVT the organization, led program. initiative Chief this our senior thrombectomy radiology, Third, on computer-assisted vascular partners. leaders vacuum organizations in as to of across our clinical working clinical
work thrombectomy doing to every vascular vacuum on readiness States now we over treating internal bringing United internationally With come. flash, as the have all our years head United are these market in thrombectomy and and across patients Indeed, grow bolt blood our the hospitals we computer-assisted and we plots bed to to about revenue this well States with products to to and XXXX. business way will XXXX expect and important innovation, our access, the in XX% comprise toe are in where we from become in available in of XX% domestic the [indiscernible], Lightning in to
By franchise of portfolio the both international as is XXXX today. new we represent in international growth and will our our our and influence outside CVT expect approximately which it in will after contrast, the XX% U.S. our products sales XXXX thrombectomy U.S.
to stewarding are still the line our a Maggie investments while free potential over years. and over next work there if be opportunities The thrombectomy but straight to be leverage plus and access. the to bigger patients we go of next business turn with our and on it growth make for profitable important purposely. results areas. stages several while we growth quarter. do ahead early over can won't commercial the challenges, profitable continue things, where financial growing the for a is on focused of significant are strong now Our focus several right think road in will many the call I'll help embolization the we these operating And over third the globally, more years We nor X
